LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 556

Search options

  1. Article ; Online: Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis.

    Lynch, Patrick M

    The lancet. Gastroenterology & hepatology

    2021  Volume 6, Issue 6, Page(s) 418–419

    MeSH term(s) Adenomatous Polyposis Coli/drug therapy ; Adenomatous Polyposis Coli/surgery ; Aspirin/therapeutic use ; Chemoprevention ; Colectomy ; Double-Blind Method ; Humans ; Mesalamine/therapeutic use
    Chemical Substances Mesalamine (4Q81I59GXC) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2021-04-02
    Publishing country Netherlands
    Document type Journal Article ; Comment
    ISSN 2468-1253
    ISSN (online) 2468-1253
    DOI 10.1016/S2468-1253(21)00102-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?

    Lynch, Patrick M

    Familial cancer

    2021  Volume 20, Issue 1, Page(s) 9–11

    MeSH term(s) Age Factors ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Aspirin/therapeutic use ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms, Hereditary Nonpolyposis/drug therapy ; Drug Administration Schedule ; Follow-Up Studies ; Humans ; Randomized Controlled Trials as Topic ; Time Factors
    Chemical Substances Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2021-01-09
    Publishing country Netherlands
    Document type Editorial
    ZDB-ID 1502496-9
    ISSN 1573-7292 ; 1389-9600
    ISSN (online) 1573-7292
    ISSN 1389-9600
    DOI 10.1007/s10689-020-00215-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Refining Risk Estimates in Hereditary Nonpolyposis Colorectal Cancer: Are We There Yet?

    Lynch, Patrick M / Pande, Mala

    JNCI cancer spectrum

    2020  Volume 4, Issue 5, Page(s) pkaa030

    Language English
    Publishing date 2020-04-27
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2515-5091
    ISSN (online) 2515-5091
    DOI 10.1093/jncics/pkaa030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Lactate Dehydrogenase Inhibitors Suppress

    Lynch, Adam / Pearson, Patrick / Savinov, Sergey N / Li, Andrew Y / Rich, Stephen M

    Pathogens (Basel, Switzerland)

    2023  Volume 12, Issue 7

    Abstract: ... Borrelia ... ...

    Abstract Borrelia burgdorferi
    Language English
    Publishing date 2023-07-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens12070962
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Colorectal Cancer Genetics Screening in the Community: Are We Ready? Can We Do It?

    Lynch, Patrick M

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

    2017  Volume 16, Issue 1, Page(s) 21–23

    MeSH term(s) Colorectal Neoplasms ; Early Detection of Cancer ; Humans ; Mass Screening
    Language English
    Publishing date 2017-10-05
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2119789-1
    ISSN 1542-7714 ; 1542-3565
    ISSN (online) 1542-7714
    ISSN 1542-3565
    DOI 10.1016/j.cgh.2017.09.049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Lactate Dehydrogenase Inhibitors Suppress Borrelia burgdorferi Growth In Vitro

    Lynch, Adam / Pearson, Patrick / Savinov, Sergey N. / Li, Andrew Y. / Rich, Stephen M.

    Pathogens. 2023 July 22, v. 12, no. 7 p.962-

    2023  

    Abstract: Borrelia burgdorferi, the causative agent of Lyme disease, has a highly reduced genome and relies heavily on glycolysis for carbon metabolism. As such, established inhibitors of lactate dehydrogenase (LDH) were evaluated in cultures to determine the ... ...

    Abstract Borrelia burgdorferi, the causative agent of Lyme disease, has a highly reduced genome and relies heavily on glycolysis for carbon metabolism. As such, established inhibitors of lactate dehydrogenase (LDH) were evaluated in cultures to determine the extent of their impacts on B. burgdorferi growth. Both racemic and enantiopure (AT-101) gossypol, as well as oxamate, galloflavin, and stiripentol, caused the dose-dependent suppression of B. burgdorferi growth in vitro. Racemic gossypol and AT-101 were shown to fully inhibit spirochetal growth at concentrations of 70.5 and 187.5 μM, respectively. Differences between racemic gossypol and AT-101 efficacy may indicate that the dextrorotatory enantiomer of gossypol is a more effective inhibitor of B. burgdorferi growth than the levorotatory enantiomer. As a whole, LDH inhibition appears to be a promising mechanism for suppressing Borrelia growth, part
    Keywords Borrelia burgdorferi ; Lyme disease ; carbon metabolism ; dose response ; enantiomers ; etiological agents ; genome ; glycolysis ; gossypol ; lactate dehydrogenase
    Language English
    Dates of publication 2023-0722
    Publishing place MDPI AG
    Document type Article ; Online
    Note Resource is Open Access
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens12070962
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  7. Article ; Online: The Case for Universal Testing of Colorectal Tumors for Microsatellite Instability: A Coming Mismatch Between Clinical and Laboratory Testing.

    Lynch, Patrick M

    Digestive diseases and sciences

    2015  Volume 60, Issue 8, Page(s) 2225–2227

    MeSH term(s) Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis ; Female ; Humans ; Male ; Mass Screening/methods
    Language English
    Publishing date 2015-08
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-015-3739-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Chemoprevention of familial adenomatous polyposis.

    Lynch, Patrick M

    Familial cancer

    2016  Volume 15, Issue 3, Page(s) 467–475

    Abstract: Familial adenomatous polyposis (FAP) has always been first and foremost a surgical disease, whose treatment with colectomy has long been known to reduce risk of premature cancer death. The notion of reducing polyp burden and potentially delaying surgical ...

    Abstract Familial adenomatous polyposis (FAP) has always been first and foremost a surgical disease, whose treatment with colectomy has long been known to reduce risk of premature cancer death. The notion of reducing polyp burden and potentially delaying surgical intervention has spawned a host of "chemoprevention" trials. In this paper I selectively review the findings from these studies, highlighting trial design issues and in particular some of the limitations of historical and existing trial endpoint measures. Nonsteroidal anti-inflammatory agents have been the most commonly employed chemopreventive agents. Sulindac, largely by historical accident, has been the most extensively studied, and is widely considered the standard of care when a clinical decision to intervene medically is made. Newer trials are evaluating combinations of agents in order to take advantage of differing mechanisms of action, in the hope of achieving synergy, as no single agent predictably or completely suppresses adenoma growth. Some of these studies and other single-agent interventions are discussed, though an exploration of the various mechanisms of action is beyond the scope of this paper. It is essential that future trials focus on the issue of "clinical benefit", not simply because the US Food and Drug Administration has insisted on it, but because only real evidence-based advances can improve the standard of medical care for FAP patients. Hence my focus on issues of trial design and clinically relevant endpoints.
    MeSH term(s) Adenomatous Polyposis Coli/prevention & control ; Adenomatous Polyposis Coli/surgery ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Aspirin/administration & dosage ; Aspirin/pharmacology ; Aspirin/therapeutic use ; Celecoxib/pharmacology ; Celecoxib/therapeutic use ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/trends ; Clinical Trials as Topic ; Colectomy/adverse effects ; Colectomy/methods ; Cyclooxygenase 2 Inhibitors/pharmacology ; Cyclooxygenase 2 Inhibitors/therapeutic use ; Drug Resistance, Neoplasm ; Drug Synergism ; Drug Therapy, Combination ; Eflornithine/pharmacology ; Eflornithine/therapeutic use ; Evidence-Based Medicine/methods ; Humans ; Prophylactic Surgical Procedures/adverse effects ; Prophylactic Surgical Procedures/methods ; Remission Induction/methods ; Sulindac/administration & dosage ; Sulindac/pharmacology ; Sulindac/therapeutic use
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Antineoplastic Agents ; Cyclooxygenase 2 Inhibitors ; Sulindac (184SNS8VUH) ; Celecoxib (JCX84Q7J1L) ; Aspirin (R16CO5Y76E) ; Eflornithine (ZQN1G5V6SR)
    Language English
    Publishing date 2016-07
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1502496-9
    ISSN 1573-7292 ; 1389-9600
    ISSN (online) 1573-7292
    ISSN 1389-9600
    DOI 10.1007/s10689-016-9901-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Endoscopic submucosal dissection using an integrated needle-type knife and insulated-tip knife in a single device.

    Nehme, Fredy / Armstrong, Anthony E / Taherian, Mehran / Lynch, Patrick M / Richards, David M / Casanova, Deanndra N / Ge, Phillip S

    VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy

    2023  Volume 8, Issue 3, Page(s) 96–99

    Abstract: Video 1Endoscopic submucosal dissection using a multifunctional endoscopic submucosal dissection knife. ...

    Abstract Video 1Endoscopic submucosal dissection using a multifunctional endoscopic submucosal dissection knife.
    Language English
    Publishing date 2023-02-09
    Publishing country United States
    Document type Journal Article
    ISSN 2468-4481
    ISSN (online) 2468-4481
    DOI 10.1016/j.vgie.2022.11.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Development and evaluation of an online, patient-driven, family outreach intervention to facilitate sharing of genetic risk information in families with Lynch syndrome.

    Pande, Mala / Peterson, Susan / Lynch, Patrick M

    Journal of medical genetics

    2021  Volume 59, Issue 6, Page(s) 589–596

    Abstract: ... of Lynch Syndrome (LS) International (LSI); (b) genetics service providers; and (3) hands-on testing ...

    Abstract Background: Identifying at-risk relatives of individuals with genetic conditions facilitates 'cascade' genetic testing and cancer prevention. Although current standards of care give mutation-positive (index) patients the responsibility of sharing genetic risk information with relatives, the communication is suboptimal, limited largely to close relatives. We developed FamilyCONNECT, a provider-mediated, patient-navigated online tool to facilitate family outreach, and assessed its feasibility, usability and acceptability.
    Methods: (1) Development of the FamilyCONNECT prototype; (2) testing using online surveys of: (a) members of Lynch Syndrome (LS) International (LSI); (b) genetics service providers; and (3) hands-on testing with patients with LS.
    Results: (1) FamilyCONNECT's features include introductory email to elicit participation, informational website/video, identity authentication/account creation, informed consent, sharing of genetic test results, pedigree expansion and process to invite at-risk relatives. (2a) 33% of the 170 LSI participants completed the survey. FamilyCONNECT's features received favourable responses from at least 79% of respondents. Unfavourable responses were for length of the consent document and mistrust of opening emailed links. (2b) Thirty-five genetics professionals responded to the providers' survey. Key perceived barriers to FamilyCONNECT's usage were privacy/confidentiality (83%), a lack of institutional resources (76%), a defined process (66%) and time (69%). (3) Ten patients navigated data collection fields and provided feedback for improvements.
    Conclusion: FamilyCONNECT tool's content and features were well received among patients with LS as well as providers. The tool could be a viable alternative to increase family outreach among patients with LS. Future efforts will focus on refining FamilyCONNECT and assessing its uptake and utilisation by patients with LS.
    MeSH term(s) Colorectal Neoplasms, Hereditary Nonpolyposis/genetics ; Family ; Genetic Testing/methods ; Humans ; Pedigree ; Surveys and Questionnaires
    Language English
    Publishing date 2021-05-18
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 220881-7
    ISSN 1468-6244 ; 0022-2593
    ISSN (online) 1468-6244
    ISSN 0022-2593
    DOI 10.1136/jmedgenet-2020-107615
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top